STOCK TITAN

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Royalty Pharma to report Q3 2023 financial results on November 8
Positive
  • None.
Negative
  • None.

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 11 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
ir@royaltypharma.com


FAQ

When will Royalty Pharma report its Q3 2023 financial results?

Royalty Pharma will report its Q3 2023 financial results on November 8, 2023.

What time will the conference call and webcast be held?

The conference call and webcast will be held at 8:00 a.m. Eastern Time on November 8, 2023.

Where can I find conference call information and view the live webcast?

You can find conference call information and view the live webcast on the 'Investors' page of Royalty Pharma's website at https://www.royaltypharma.com/investors/news-and-events/events.

Will there be a replay of the conference call and webcast available?

Yes, a replay of the conference call and webcast will be archived on Royalty Pharma's website for at least 30 days.

Royalty Pharma plc

NASDAQ:RPRX

RPRX Rankings

RPRX Latest News

RPRX Stock Data

10.96B
380.91M
13.17%
72.78%
3.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK